CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

Cancers

JoseManuel Perez-Garcia¹  Antonio Llombart¹  Debora de Melo Gagliato²  Antonio C Buzaid²  Javier Cortes³ 

[1] Baselga Institute of Oncology, Quiron University Hospital Barcelona, 08023 Barcelona, Spain;Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, 01323001 São Paulo, Brazil;Ramon y Cajal University Hospital, 28034 Madrid, Spain;

关键词: metastatic breast cancer;    CDK4/6 inhibitors;    hormone receptor-positive breast cancer;   

DOI  :  10.3390/cancers12092480

来源: DOAJ

【 摘 要 】

Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.

【 授权许可】

Unknown